With Donald Trump set to become the next US President, India Inc on Wednesday sought greater access for the country’s pharmaceutical products in the US market and mobility of skilled labour.
The industry also tried to allay concerns related to the billionaire businessman, expressing confidence that apprehensions linked to him would ‘certainly prove wrong’, saying it looks forward to take the bilateral economic engagement to a greater level under the Trump administration.
“We hope that challenges relating to mobility of skilled labour, market access for pharmaceutical products from India, and financial services institutions and SMEs will be addressed,” CII President Naushad Forbes said.
“Our primary focus areas with the US have been standards, manufacturing competitiveness, defence collaboration and mobility of high skilled labour. We look forward to working with the Trump administration to further cement this critical partnership.” In a stunning result, Trump beat seasoned politician Hillary Clinton in the knife-edge polls, defying the odds to become the 45th US President after starting off as a rank political outsider.
Seeking to ‘bind the wounds of division’ after a bitter and divisive campaign, Trump pledged to be the President for all Americans and asked Republicans, Democrats and independents across the country to come together as one united people.
Skipping policy issues in his victory speech, the 70-year-old President-elect congratulated his Democrat rival Hillary Clinton with whom he had crossed words during the long, often ugly campaign, saying she fought very hard.